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Abstract
Objective To explore the value of olfactory identification deficits as a predictor of cerebral β-amyloid status and other mark-
ers of brain health in cognitively normal adults aged ~ 70 years.
Methods Cross-sectional observational cohort study. 389 largely healthy and cognitively normal older adults were recruited 
from the MRC National Survey of Health and Development (1946 British Birth cohort) and investigated for olfactory iden-
tification deficits, as measured by the University of Pennsylvania Smell Identification Test. Outcome measures were imag-
ing markers of brain health derived from 3 T MRI scanning (cortical thickness, entorhinal cortex thickness, white matter 
hyperintensity volumes); 18F florbetapir amyloid-PET scanning; and cognitive testing results. Participants were assessed at 
a single centre between March 2015 and January 2018.
Results Mean (± SD) age was 70.6 (± 0.7) years, 50.8% were female. 64.5% had hyposmia and 2.6% anosmia. Olfaction 
showed no association with β-amyloid status, hippocampal volume, entorhinal cortex thickness, AD signature cortical thick-
ness, white matter hyperintensity volume, or cognition.
Conclusion and relevance In the early 70s, olfactory function is not a reliable predictor of a range of imaging and cognitive 
measures of preclinical AD. Olfactory identification deficits are not likely to be a useful means of identifying asymptomatic 
amyloidosis. Further studies are required to assess if change in olfaction may be a proximity marker for the development of 
cognitive impairment.
Keywords Alzheimer’s disease · Olfactory impairment · Neuroimaging
Introduction
Simple, non-invasive markers of preclinical Alzheimer’s dis-
ease (AD) are needed. Odour identification (OI) deficits have 
been proposed as a potential risk marker for AD. Clinically, 
individuals diagnosed with AD and mild cognitive impair-
ment (MCI) have poorer OI, and OI deficits are associated 
with cognitive decline and conversion to MCI and AD [1]; 
and AD pathology affects olfactory pathways in older adults 
[2] and animal models [3].
While the evidence for these associations in clinically 
defined groups is strong, the evidence regarding imaging 
biomarkers is more mixed. Table 1 summarises the previous 
literature investigating associations between OI and imag-
ing markers of preclinical AD. Considering the two larg-
est cohorts, Vassilaki et al. [4] and Growdon et al. [5] each 
found associations between poorer OI and imaging markers 
of neurodegeneration. Amyloid status was positively associ-
ated with poorer OI in the former, and at trend level in the 
latter study. In smaller studies, associations were not found 
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[6, 7], or only seen when individuals with MCI or AD were 
included in pooled analyses [8, 9]. Associations between 
poorer OI and AD signature cortical thickness, and lower 
hippocampal volumes have been described [4, 7, 10, 11]. 
Associations with entorhinal cortex thickness or white mat-
ter hyperintensity volume have been present or absent in 
various studies [4–6, 10, 11].
A useful marker for preclinical AD would be positive 
early in the disease course, allowing a window for treatment. 
As the prevalence of AD pathology increases steeply with 
age, younger cohorts may be useful to investigate the earlier 
stages of disease.
In the current study, we explored associations between 
OI and markers of cerebral β-amyloid deposition (using 
18F-florbetapir PET scanning), neurodegeneration, and cog-
nition in a uniquely well-characterised cohort of near identi-
cal age drawn from the MRC National Survey of Health and 
Development (NSHD; the British 1946 birth cohort).
Methods
Participants
The Insight 46 study included 502 older adults recruited 
from the NSHD [12], a representative sample of singleton 
births in one week in March 1946 originally comprising 
5326 individuals who have been followed prospectively 
throughout their lives [13]. Ethical approval was granted 
by the National Research Ethics Service Committee Lon-
don (reference 14/LO/1173); participants provided written 
informed consent.
Participants attended a one-day visit at University Col-
lege London between May 2016 and January 2018 (age 
69–71 years). The cohort profile and recruitment informa-
tion has been published [14]. We excluded participants with-
out high-quality imaging (T1-weighted MRI and amyloid-
PET), and those with mild cognitive impairment (MCI), 
neurodegenerative conditions, or conditions likely to affect 
olfactory function including previous sinus surgery or upper 
respiratory tract infection (Supplementary data).
Olfactory testing
The University of Pennsylvania Smell Identification Test 
(UPSIT) is a validated “scratch-and-sniff” test comprising 
40 micro-encapsulated odorants, with four-option forced-
choice answers [15]. Participants completed the “British” 
version at the study visit or soon thereafter. Where there 
was missing data for four or fewer items, a correction fac-
tor of 0.25 per missing item was applied, in line with other 
studies [16].
For categorical analyses, hyposmia was defined as 
UPSIT score ≤ 33 for males, ≤ 34 for females, and anosmia 
as UPSIT score ≤ 18 [15]. Normative data for the UPSIT 
British version have not been published; a comparison to 
norms for the UPSIT American version is shown in Table 1.
Neuropsychological testing
The cognitive battery included the Mini-Mental Status 
Examination (MMSE), Logical Memory, Digit-Symbol 
Substitution Test, and the Face-Name test [12]. These tests 
were combined into a modified version of the Preclinical 
Alzheimer Clinical Composite (PACC) score as described 
in Lu et al. [17].
Imaging
Participants underwent PET-MRI scanning on the same 3-T 
Siemens Biograph mMR scanner [12]. β-amyloid deposition 
was assessed over a 10-min period, 50 min after injection 
of 18F-florbetapir (370 mBq). A standardised uptake value 
ratio (SUVR) was generated from a grey matter cortical 
composite, with eroded white matter as the reference region. 
Gaussian mixture models determined a SUVR cut-point of 
0.6104 to categorise binary amyloid status.
Hippocampal volume, entorhinal cortex thickness and 
AD signature cortical thickness were used as markers of 
neurodegeneration [4, 5]. Hippocampal volumes were deter-
mined using STEPS [18] with manual edits where appropri-
ate. AD signature cortical thickness (a composite of tem-
poral cortex regions as described in [19]) and entorhinal 
cortex measurements were determined using Freesurfer 6.0. 
Total intracranial volume was calculated using SPM12 (Sta-
tistical Parametric Mapping, https ://www.fil.ion.ucl.ac.uk/
spm/) [20]. White matter hyperintensity volume (WMHV) 
was derived using Bayesian Model Selection (BaMoS) [21].
Statistical methods
Data were analysed using Stata 14.1 (StataCorp LP). Chi-
squared or Wilcoxon rank-sum tests were used for unad-
justed analyses comparing OI category with binary or 
continuous demographic variables, respectively. Logistic 
regression was used for adjusted analysis of (binary) amy-
loid status, linear regression for hippocampal volumes, AD 
signature cortical thickness, entorhinal cortex thickness and 
PACC score. As WMHV was non-normally distributed, we 
used a general linear model with gamma log link. For each 
of these outcomes, we fitted models with continuous UPSIT 
score or OI impairment category as the predictor variable, 
and age, sex, and (where appropriate) TIV as covariates.
Journal of Neurology 
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Results
Full data on 389 individuals were available for analysis: 
mean age at visit was 70.6 (SD 0.68) years, and 50.8% 
were female. Table 1 compares the distribution of UPSIT 
scores in this cohort with those of a large cohort of simi-
lar age assessed using the UPSIT (American version); the 
distribution of scores is similar.
Demographic and background features of the nor-
mosmic (32.9%), hyposmic (64.5%) and anosmic (2.6%) 
groups are shown in Table 1. There were no significant 
differences in sex, age, socio-economic position, smok-
ing, history of head injury, ApoE4 status, or MMSE score 
between groups.
There was no significant relationship between continu-
ous UPSIT score and binary amyloid status, adjusting 
for age and sex (OR 1.04, 95% CI 0.98–1.10, p = 0.24). 
There was no evidence that adding UPSIT score to a base 
model of age and sex improved prediction of amyloid sta-
tus (Fig. 1).
Hippocampal volume, entorhinal cortex thickness, corti-
cal thickness, PACC, or WMHV was not associated with 
continuous UPSIT scores, or when comparing groups cat-
egorically (Table 2) after adjusting for age and sex. There 
was similarly no relationship between UPSIT score and any 
of the components of the PACC (data not shown).
Discussion
In this study of 389 cognitively normal individuals around 
the age of 70 years, our main findings were (1) ~ 2/3 of indi-
viduals fulfil criteria for hyposmia, and (2) that there were 
no associations between low scores on olfactory identifica-
tion testing and imaging evidence of β-amyloid pathology, 
Fig. 1  Receiver operating char-
acteristic curve illustrating the 
predictive value of age, sex and 
UPSIT score for amyloid status. 
Area under the curve for age 
and sex alone, 0.517 (95% con-
fidence interval: 0.444–0.590), 
versus 0.545 (95% confidence 
interval 0.465–0.624) when 
UPSIT score is added to the 
model p = 0.466). This indicates 
that the addition of UPSIT score 
has very limited additional 
discriminatory value to predict 
amyloid status
Table 2  Comparison of 
distribution of UPSIT scores 
in the current study (UPSIT: 
British) to previously published 
normative values (UPSIT: 
American), by sex [24]
Percentile UPSIT score
Males Females
UPSIT: American, age 
70–74 (n = 77)
UPSIT: British, age 
69–71 (n = 191)
UPSIT: American, age 
70–74 (n = 87)
UPSIT: Brit-
ish, age 69–71 
(n = 198)
99 39 39 40 38
75 34–35 35 35–36 35
50 29–30 32 32–33 33
25 24 28 27–28 31
 Journal of Neurology
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neurodegeneration or cerebrovascular disease, or cognitive 
performance.
The strongest associations between olfaction and imaging 
metrics relevant to AD were reported in the Mayo Clinic 
cohort [4], which also has the highest average age (79 years). 
The Harvard cohort (mean age 74 years) [5] found a trend 
level association with amyloid status, and significant asso-
ciations with imaging markers of neurodegeneration. Noting 
that our cohort was ~ 10 and 5 years younger than these, 
respectively, and as older individuals would be expected to 
have a shorter time to AD onset, this suggests that if OI 
impairment is not a useful screening tool for asymptomatic 
pathology, it may however be useful as a proximity marker 
for the emergence of cognitive impairment. The finding in 
smaller studies that associations between OI and imaging 
markers were strengthened by the inclusion of individuals 
with MCI (who are closer to disease onset) may also indicate 
this [8, 9]
Limitations of this study include its cross-sectional design 
and lack of a marker of tau pathology, as there is evidence 
from pathological [2] and biomarker [7, 22] studies that tau 
deposition may be more closely linked to olfactory changes. 
Longer term follow-up of this cohort and the addition of 
markers of tau pathology will be able to address the latter 
and the potential proximal relationship of OI to the develop-
ment of cognitive impairment. Whether or not olfactory loss 
than can be seen in patients infected with Covid-19 relates 
to damage to olfactory epithelium or neuronal injury is the 
subject of ongoing debate, but at the current time, there is 
no evidence that this is related to Alzheimer pathology [23].
In summary, the high prevalence of OI impairment in 
populations at this age and lack of relationship between OI 
Table 3  Associations between demographic factors and olfactory identification impairment
SEP socio-economic position, MMSE mini-mental status examination
a p value compared to normosmia, determined by chi-square test (categorical variables) or Wilcoxon rank-sum test (continuous variables)
b n = 249 for this variable
Normosmia  (n = 128) Hyposmia  (n = 251) pa Anosmia (n = 10) pa
Sex, female [n, (%)] 62 (48.4) 134 (53.4) 0.362 2 (20.9) 0.082
Age, years [mean, (SD)] 70.7 (0.62) 70.6 (0.70) 0.181 70.6 (0.95) 0.790
SEP, manual occupations [n, (%)] 22 (17.2) 34 (13.6) 0.345 2 (20.0) 0.821
Current or former smoking [n, (%)] 80 (62.5) 166 (66.1) 0.483 6 (60.0) 0.875
Head injury prior to age 69–71 [n, (%)] 22 (17.2) 28 (11.2) 0.101 2 (20.0) 0.821
ApoE 4 carrier [n, (%)] 39 (29.7) 72 (28.9)b 0.472 4 (40) 0.495
MMSE score [median, (IQR)] 30 (29–30) 30 (29–30) 0.973 29.5 (29–30) 0.565
Table 4  Associations between continuous and categorical UPSIT scores and imaging outcomes in 389 cognitively normal individuals at age 
69–71
a Adjusted for age and sex
b Adjusted for age, sex and total intracranial volume
c Expressed as the mean of right and left
d n = 377 for this outcome
e Expressed as exponentiated β coefficient; value represents the ratio change in WMHV per 1 point increase in UPSIT score, or between groups
Continuous analyses Categorical analyses
UPSIT score Hyposmia Anosmia
β 95% CI p β 95% CI p β 95% CI p
Associations by linear regression (β coefficient)
Hippocampal volume (mL)b,c − 0.002 − 0.004, 0.011 0.805 − 0.075 − 0.200, 0.050 0.239 − 0.162 − 0.540, 0.217 0.401
Entorhinal cortex thickness (mm)a,c 0.001 − 0.004, 0.006 0.671 0.010 − 0.039, 0.059 0.693 − 0.041 − 0.191, 0.108 0.587
Cortical thickness  (mm)a 0.001 − 0.001, 0.003 0.156 − 0.003 − 0.022, 0.017 0.771 0.001 − 0.058, 0.059 0.986
Global cognitive score (modified PACC)a − 0.003 − 0.017, 0.011 0.657 0.001 − 0.141, 0.140 0.992 0.252 − 0.172, 0.677 0.244
Associations by generalised linear model (exponentiated β coefficient)
White matter hyperintensity volume 
(mL)b,d
0.992e 0.967, 1.016 0.609 1.153e 0.906, 1.468 0.247 1.280e 0.624, 2.628 0.501
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and markers of β-amyloid and neurodegeneration we find, 
indicate that the UPSIT is unlikely to be a reliable predictor 
of preclinical AD in its very earliest stages (Tables 3, 4).
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